Physician profile
Charles W Marks
NPI 1184635518
$8,047.62
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $871 · 2021: $2,810 · 2022: $1,818 · 2023: $827 · 2024: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.53 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,062.52 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $832.26 | 2019-2023 | Ozempic |
| Paratek Pharmaceuticals, INC. | $812.00 | 2021 | |
| Lilly USA, LLC | $804.43 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $401.13 | 2020-2021 | |
| Amarin Pharma, INC. | $364.52 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.90 | 2019-2022 | |
| Pfizer INC. | $305.33 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $299.63 | 2019-2024 | Xarelto |
| Amgen INC. | $276.63 | 2019-2024 | Repatha |
| Allergan, INC. | $269.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $231.17 | 2019-2022 | |
| Daiichi Sankyo INC. | $186.08 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $159.88 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.09 | 2021-2022 | |
| Esperion Therapeutics, INC. | $120.16 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $76.42 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $53.81 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $35.67 | 2020 | |
| Zyla Life Sciences, INC. | $34.64 | 2019-2020 | |
| Dexcom, INC. | $34.56 | 2022 | |
| Astellas Pharma US INC | $30.79 | 2019 | |
| Nestle Healthcare Nutrition INC. | $22.52 | 2021 | |
| Sanofi Pasteur INC. | $21.88 | 2019 | |
| Eisai INC. | $16.24 | 2019 | |
| Genentech USA, INC. | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.